HomeNewsBusinessMarketsMoneycontrol Pro Panorama | The antidote to tariffs

Moneycontrol Pro Panorama | The antidote to tariffs

In today’s edition of Pro Panorama: Pharma’s new tariff pill, shifting market equations, Accenture’s earnings mojo, hand that drives the economy and much more

September 26, 2025 / 15:26 IST
Story continues below Advertisement
-
-

Dear Reader,

When a door closes, look for an open window. This perhaps sums up America’s tariffs that keep coming and the response to them by trading partners, including us. US President Donald Trump’s fresh round of tariffs, now on branded pharmaceuticals, select furniture and heavy trucks, have tossed a fresh fistful of uncertainty towards investors. Trading partners would now scramble to handle this latest salvo and the keywords near-shoring and friend-shoring are being tossed around again.

Story continues below Advertisement

For Indian drugmakers, it is more a mixed blessing. As our research piece here suggests, 95 percent of Indian pharma exports to America are generic drugs, right now outside the tariff firing line. In fact, drugmakers could benefit as branded prescription drugs become expensive due to tariffs, which help generic medicines to take the lead in the US market. Even though stocks of pharmaceutical companies lost 4 percent in early trade today, it seems we have dodged this bullet for now.

What will hurt Indian companies is the exponential hike in H1B visa fees that will leave the IT industry -- the highest sponsor of worker visas to the US -- with burgeoning costs. The IT industry has not been able to catch a break over the past several years as employment challenges from artificial intelligence (AI), and competition from global capability centres (GCC) and now visa costs have hammered it. How does the H1B visa hike make matters worse is explored by Ananya Roy here in her piece.